Share on StockTwits

Regeneron Pharmaceuticals (NASDAQ:REGN) major shareholder Sanofi bought 212,400 shares of the company’s stock in a transaction dated Tuesday, July 1st. The shares were purchased at an average cost of $300.20 per share, for a total transaction of $63,762,480.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

A number of analysts have recently weighed in on REGN shares. Analysts at Zacks upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Wednesday, June 25th. They now have a $334.00 price target on the stock. Separately, analysts at Goldman Sachs reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, June 24th. Six research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $344.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded up 0.85% during mid-day trading on Thursday, hitting $311.16. The stock had a trading volume of 636,673 shares. Regeneron Pharmaceuticals has a 1-year low of $225.78 and a 1-year high of $352.49. The stock has a 50-day moving average of $299.8 and a 200-day moving average of $300.0. The company has a market cap of $30.714 billion and a price-to-earnings ratio of 88.46.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.58 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.94 by $0.36. The company had revenue of $626.00 million for the quarter, compared to the consensus estimate of $609.04 million. During the same quarter in the prior year, the company posted $1.78 earnings per share. The company’s quarterly revenue was up 42.3% on a year-over-year basis. On average, analysts predict that Regeneron Pharmaceuticals will post $9.90 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.